[
  {
    "ts": null,
    "headline": "Top 50 High Quality Dividend Growth Stocks - November 2024",
    "summary": "Track 50 high-quality dividend stocks for potential investment opportunities and November's performance vs. SPY and SCHD. Read an analysis here.",
    "url": "https://finnhub.io/api/news?id=5c72b4022da9322f4b2a3445f35cc7aeb4cfcd455fc733cbbe0ac4af4f7edf1e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733182512,
      "headline": "Top 50 High Quality Dividend Growth Stocks - November 2024",
      "id": 131746074,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1484268315/image_1484268315.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Track 50 high-quality dividend stocks for potential investment opportunities and November's performance vs. SPY and SCHD. Read an analysis here.",
      "url": "https://finnhub.io/api/news?id=5c72b4022da9322f4b2a3445f35cc7aeb4cfcd455fc733cbbe0ac4af4f7edf1e"
    }
  },
  {
    "ts": null,
    "headline": "Four oral GLP-1R products in Phase III trials as race intensifies",
    "summary": "GLP-1R injectable drugs are effective in treating obesity, but their success points to a gap in the market: oral alternatives.",
    "url": "https://finnhub.io/api/news?id=cbd42131a5614c5ddc638e5d7b112eb5d58d84fbf7b15e0bef72605084b1559f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733163736,
      "headline": "Four oral GLP-1R products in Phase III trials as race intensifies",
      "id": 131740598,
      "image": "https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2024/12/shutterstock_156633113-1.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "GLP-1R injectable drugs are effective in treating obesity, but their success points to a gap in the market: oral alternatives.",
      "url": "https://finnhub.io/api/news?id=cbd42131a5614c5ddc638e5d7b112eb5d58d84fbf7b15e0bef72605084b1559f"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Flat on Mixed Obesity-Drug Fortunes - Health Care Roundup",
    "summary": "Health Care Flat on Mixed Obesity-Drug Fortunes - Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=f8d2be7acf23917d52d2eb7d7f00dc4d80ecc95124a8798eb0b3cd59695492e5",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733160060,
      "headline": "Health Care Flat on Mixed Obesity-Drug Fortunes - Health Care Roundup",
      "id": 131774953,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Health Care Flat on Mixed Obesity-Drug Fortunes - Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=f8d2be7acf23917d52d2eb7d7f00dc4d80ecc95124a8798eb0b3cd59695492e5"
    }
  },
  {
    "ts": null,
    "headline": "Diabetes advocacy group discourages use of compounded GLP-1 drugs",
    "summary": "The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.",
    "url": "https://finnhub.io/api/news?id=6deb7225d8c525fd18965a1e3825f36f0a563df562a2a413ad92aa9c906f26d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733159991,
      "headline": "Diabetes advocacy group discourages use of compounded GLP-1 drugs",
      "id": 131753678,
      "image": "https://imgproxy.divecdn.com/wrMA67fihBFXR-4sKwTsSNmkPOaDDJfkjT74mwMhf5I/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMTUwMDMzMjU3LmpwZw==.webp",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that has gripped the FDA and compounding pharmacies over the past few months.",
      "url": "https://finnhub.io/api/news?id=6deb7225d8c525fd18965a1e3825f36f0a563df562a2a413ad92aa9c906f26d0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=1c336222a93955bd82157bfc4620adeea64029a3e27429ec9545ebee797bde35",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733157180,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 131774954,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=1c336222a93955bd82157bfc4620adeea64029a3e27429ec9545ebee797bde35"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Eli Lilly and Company (LLY) Among Ken Fisher’s Top Stock Picks Heading Into 2025?",
    "summary": "We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against Ken Fisher’s other top stock picks. Ken Fisher is the founder of Fisher Asset Management, a financial adviser that he […]",
    "url": "https://finnhub.io/api/news?id=84d3112a026480a4042796a77e42f3ea1fa184e09ff059be257025f8dd9f90e7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733156562,
      "headline": "Why Is Eli Lilly and Company (LLY) Among Ken Fisher’s Top Stock Picks Heading Into 2025?",
      "id": 131741237,
      "image": "https://s.yimg.com/ny/api/res/1.2/UjoPACeXPFyN.4G.yM_TTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/860932d32d923713fdffa5b1d444d8a3",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the Billionaire Ken Fisher’s Top 15 Stock Picks Heading Into 2025. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against Ken Fisher’s other top stock picks. Ken Fisher is the founder of Fisher Asset Management, a financial adviser that he […]",
      "url": "https://finnhub.io/api/news?id=84d3112a026480a4042796a77e42f3ea1fa184e09ff059be257025f8dd9f90e7"
    }
  }
]